Background: Glioblastoma multiforme (GBM) is characterized by heterogeneous cell populations. Among these, the Glioblastoma Stem Cells (GSCs) fraction shares some similarities with Neural Stem Cells. GSCs exhibit enhanced resistance to conventional chemotherapy drugs. Our previous studies demonstrated that the activation of M2 muscarinic acetylcholine receptors (mAChRs) negatively modulates GSCs proliferation and survival. The aim of the present study was to analyze the ability of the M2 dualsteric agonist Iper-8-naphthalimide (N-8-Iper) to counteract GSCs drug resistance. Methods: Chemosensitivity to M2 dualsteric agonist N-8-Iper and chemotherapy drugs such as temozolomide, doxorubicin, or cisplatin was evaluated in vitro by MTT assay in two different GSC lines. Drug efflux pumps expression was evaluated by RT-PCR and qRT-PCR. Results: By using sub-toxic concentrations of N-8-Iper combined with the individual chemotherapeutic agents, we found that only low doses of the M2 agonist combined with doxorubicin or cisplatin or temozolomide were significantly able to counteract cell growth in both GSC lines. Moreover, we evaluated as the exposure to high and low doses of N-8-Iper downregulated the ATP-binding cassette (ABC) drug efflux pumps expression levels. Conclusions: Our results revealed the ability of the investigated M2 agonist to counteract drug resistance in two GSC lines, at least partially by downregulating the ABC drug efflux pumps expression. The combined effects of low doses of conventional chemotherapy and M2 agonists may thus represent a novel promising pharmacological approach to impair the GSC-drug resistance in the GBM therapy.

The combined treatment with chemotherapeutic agents and the dualsteric muscarinic agonist iper-8-naphthalimide affects drug resistance in glioblastoma stem cells / Guerriero, C.; Matera, C.; Del Bufalo, D.; De Amici, M.; Conti, L.; Dallanoce, C.; Tata, A. M.. - In: CELLS. - ISSN 2073-4409. - ELETTRONICO. - 10:8(2021), pp. 187701-187716. [10.3390/cells10081877]

The combined treatment with chemotherapeutic agents and the dualsteric muscarinic agonist iper-8-naphthalimide affects drug resistance in glioblastoma stem cells

Conti L.;
2021-01-01

Abstract

Background: Glioblastoma multiforme (GBM) is characterized by heterogeneous cell populations. Among these, the Glioblastoma Stem Cells (GSCs) fraction shares some similarities with Neural Stem Cells. GSCs exhibit enhanced resistance to conventional chemotherapy drugs. Our previous studies demonstrated that the activation of M2 muscarinic acetylcholine receptors (mAChRs) negatively modulates GSCs proliferation and survival. The aim of the present study was to analyze the ability of the M2 dualsteric agonist Iper-8-naphthalimide (N-8-Iper) to counteract GSCs drug resistance. Methods: Chemosensitivity to M2 dualsteric agonist N-8-Iper and chemotherapy drugs such as temozolomide, doxorubicin, or cisplatin was evaluated in vitro by MTT assay in two different GSC lines. Drug efflux pumps expression was evaluated by RT-PCR and qRT-PCR. Results: By using sub-toxic concentrations of N-8-Iper combined with the individual chemotherapeutic agents, we found that only low doses of the M2 agonist combined with doxorubicin or cisplatin or temozolomide were significantly able to counteract cell growth in both GSC lines. Moreover, we evaluated as the exposure to high and low doses of N-8-Iper downregulated the ATP-binding cassette (ABC) drug efflux pumps expression levels. Conclusions: Our results revealed the ability of the investigated M2 agonist to counteract drug resistance in two GSC lines, at least partially by downregulating the ABC drug efflux pumps expression. The combined effects of low doses of conventional chemotherapy and M2 agonists may thus represent a novel promising pharmacological approach to impair the GSC-drug resistance in the GBM therapy.
2021
8
Guerriero, C.; Matera, C.; Del Bufalo, D.; De Amici, M.; Conti, L.; Dallanoce, C.; Tata, A. M.
The combined treatment with chemotherapeutic agents and the dualsteric muscarinic agonist iper-8-naphthalimide affects drug resistance in glioblastoma stem cells / Guerriero, C.; Matera, C.; Del Bufalo, D.; De Amici, M.; Conti, L.; Dallanoce, C.; Tata, A. M.. - In: CELLS. - ISSN 2073-4409. - ELETTRONICO. - 10:8(2021), pp. 187701-187716. [10.3390/cells10081877]
File in questo prodotto:
File Dimensione Formato  
cells-10-01877-v2.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 3.28 MB
Formato Adobe PDF
3.28 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/334627
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
  • OpenAlex ND
social impact